Amendments to the Claims:

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1.- 53. (Cancelled)

54. (New) A method of treating an individual having a condition, comprising the step of administering to an individual a carbamoyl ester, wherein the carbamoyl ester is selected from the group consisting of:


,

,

,

,

,

, and


wherein

R_1 and R_2 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl;

R_3, R_4, and R_5 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl; and

further wherein the condition is selected from a central nervous system condition, a peripheral nervous system condition and an autonomic nervous system condition.

55. (New) A method of treating an individual having a central nervous system condition, comprising the step of administering to an individual a carbamoyl ester having the formula:



wherein

R_1 and R_2 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl; and

R_3, R_4, and R_5 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl.

56. (New) The method of claim 55, wherein the central nervous system condition is selected from the group consisting of Parkinson's disease, a memory impairment and a cognitive impairment.

57. (New) The method of claim 56, wherein the memory impairment is in a human associated with at least one condition selected from the group consisting of Alzheimer's

disease, age-associated memory loss, an impairment in memory consolidation, an impairment in short term memory, an impairment in long term memory, mild cognitive impairment, and multiple sclerosis.

58. (New) The method of claim 54, wherein at least one of R_3, R_4, and R_5 is unsubstituted alkyl.

59. (New) The method of claim 54, wherein one of R_1 or R_2 is selected from the group consisting of H, substituted alkyl, and unsubstituted alkyl and the remaining R_1 or R_2 is selected from the group consisting of substituted aralkyl and unsubstituted aralkyl.

60. (New) The method of claim 59, wherein one of R_1 or R_2 is unsubstituted alkyl and the remaining R_1 or R_2 is substituted aralkyl.

61. (New) The method of claim 54, wherein the carbamoyl ester is



62. (New) The method of claim 61, wherein the carbamoyl ester is



63. (New) The method of claim 62, wherein the carbamoyl ester is selected from the group consisting of:


3

,


6

,



7

,



9

,



11

,



18

, and



20

.

64. (New) The method of claim 63, wherein the carbamoyl ester is



7

.

65. (New) The method of claim 54, wherein the individual is a human.

66. (New) A method of treating an individual having a central nervous system condition, comprising the step of administering to an individual a carbamoyl ester having the formula:



wherein

R_1 and R_2 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl; and

R_3, R_4, and R_5 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl.

67. (New) The method of claim 66, wherein the central nervous system condition is selected from the group consisting of Parkinson's disease, a memory impairment and a cognitive impairment.

68. (New) The method of claim 67, wherein the memory impairment is in a human associated with at least one condition selected from the group consisting of Alzheimer's disease, age-associated memory loss, an impairment in memory consolidation, an impairment in short term memory, an impairment in long term memory, mild cognitive impairment, and multiple sclerosis.

69. (New) The method of claim 66, wherein at least one of R_3, R_4, and R_5 is unsubstituted alkyl.

70. (New) The method of claim 66, wherein one of R_1 or R_2 is selected from the group consisting of H, substituted alkyl and unsubstituted alkyl and the remaining R_1 or R_2 is selected from the group consisting of substituted aralkyl and unsubstituted aralkyl.

71. (New) The method of claim 70, wherein one of R_1 or R_2 is unsubstituted alkyl and the remaining R_1 or R_2 is substituted aralkyl.

72. (New) The method of claim 66, wherein the carbamoyl ester is



73. (New) The method of claim 66, wherein the carbamoyl ester is



13

or



14

.

74. (New) The method of claim 66, where the individual is a human.

75. (New) A method of increasing acetylcholine, comprising the step of administering to an individual a carbamoyl ester, wherein the carbamoyl ester is selected from:


,

,

,

,

,

, and


wherein

R_1 and R_2 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl; and

R_3, R_4, and R_5 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl.

76. (New) The method of claim 75, wherein at least one of R_3, R_4, and R_5 is unsubstituted alkyl.

77. (New) The method of claim 75, wherein one of R_1 or R_2 is selected from the group consisting of H, substituted alkyl and unsubstituted alkyl and the remaining R_1 or R_2 is selected from substituted aralkyl and unsubstituted aralkyl.

78. (New) The method of claim 77, wherein one of R_1 or R_2 is unsubstituted alkyl and the remaining R_1 or R_2 is substituted aralkyl.

79. (New) A method of treating a cholinergic deficiency, comprising the step of administering to an individual a carbamoyl ester having the formula:



,

,

,

,

,

, and

wherein

R_1 and R_2 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl; and

R_3, R_4, and R_5 are each, independently or in combination, selected from the group consisting of a hydrogen, an unsubstituted alkyl, a substituted alkyl, an unsubstituted aralkyl, a substituted aralkyl, an unsubstituted heteroalkyl, a substituted heteroalkyl, an unsubstituted heteroaralkyl, a substituted heteroaralkyl, an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl, a substituted heteroaryl, an unsubstituted cycloalkyl, a substituted cycloalkyl, an unsubstituted heterocycloalkyl and a substituted heterocycloalkyl.

80. (New) The method of claim 80, wherein the cholinergic deficiency in the individual is Alzheimer's disease.